JOURNAL OF PRACTICAL HEPATOLOGY ›› 2015, Vol. 18 ›› Issue (2): 178-181.doi: 10.3969/j.issn.1672-5069.2015.02.017

• Orignal Article • Previous Articles     Next Articles

Efficacy of Shengmai,alprostadil and reduced glutathione in treatment of patients with systemic inflammatory response syndrome

Zhan Guoqing, Tan Huabing, Li Fang, et al.   

  1. Department of Infectious Disease,People’s Hospital,Hubei University of Medicine,Shiyan 442000,Hubei Province,China
  • Received:2014-08-11 Online:2015-03-10 Published:2016-02-19

Abstract: Objective To investigate the efficacy of Shengmai,a herbal medicine,alprostadil and reduced glutathione in treatment of patients with systemic inflammatory response syndrome(SIRS). Methods Sixty-two patients with SIRS were randomly divided into two groups. Patients in control group(n=28) received basic treatment,and patients in treatment group(n=34) were given Shengmai,alprostadil and reduced glutathione injections intravenously for 7 days at the basic treatment. The serum levels of serum interleukin 6(IL-6),IL-10,tumor necrosis factor alpha (TNF-α) and C reactive protein (CRP),and incidences of multiple organ dysfunction syndrome(MODS) as well as mortality rates in the two groups were recorded and compared. Results After 7 day treatment,the levels of serum IL-6,TNF-α,IL-10 and CRP in patients in treatment group were(98.5±18.5) pg/ml,(31.8±9.5) ng/ml,(25.6±7.8) mg/ml and (92.5±24.5) μg/L,significantly lower than those in the controls [(180.6±34.5) pg/ml,(58.6±15.8) ng/ml,(40.5±10.2) mg/ml and 72.8±18.0) μg/L,respectively,P<0.01];The incidence of MODS in control patients was 35.6%,significantly higher than that in treatment group (11.8%,P<0.05); The mortality rates of patients in treatment and in control group were 5.9% and 21.4%,respectively,which had no significant statistical difference(P>0.05). Conclusions Shenmai,alprostadil and reduced glutathione injection were effective in blocking SIRS process,which might be related to the inhibition of inflammatory response.

Key words: Systemic inflammatory response syndrome, Shengmai injection, Alprostadil, Reduced glutathione, Therapy